- Pakistan’s effective diplomacy for resolving regional conflicts acknowledged RADIO PAKISTAN
- Pakistan seeks economic dialogue with US, flags regional security concerns Dawn
- Pakistan, US pledge to boost economic, security ties The Express Tribune
Author: admin
-
Pakistan's effective diplomacy for resolving regional conflicts acknowledged – RADIO PAKISTAN
-
‘Anger, grief and tear gas:’ outrage in Minnesota after ICE shooting
When Susie Hayward heard that a woman had been shot and killed by an immigration agent in downtown Minneapolis on Wednesday, she rushed to the scene to bear witness. What she found was “anger, grief and tear gas”.
“The federal government has…
Continue Reading
-
Durham man met his best friend through men’s wellness group
Tom BurgessNorth East and Cumbria
Man Up DurhamMan Up Durham is a volunteer-run men’s wellness group Joining a men’s wellness group has helped a man “get his spark back” after a bad break-up and introduced him to his new best friend.
Tyler Bond, 40,…
Continue Reading
-
Rokid and Ant International Announce Integration of Smart Glasses Payment Capability
Las Vegas (ANTARA/PRNewswire)- Rokid, a global pioneer in human-computer interaction and augmented reality, announced a strategic collaboration with Ant International, a leading global digital payment, digitisation, and financial…Continue Reading
-
Shaping Somalia’s environmental sustainability: the role of institutional quality, renewable energy, economic growth, and financial globalization on load capacity factor
Arora, N. K. et al. Environmental sustainability: Challenges and viable solutions. Environ. Sustain. 1(4), 309–340 (2018).
Feng, Y. et al. Bridging resource disparities for sustainable…
Continue Reading
-
What are potential ‘hard ways’ Trump could try to take Greenland? | Donald Trump News
Since taking the White House in January last year, President Donald Trump has repeatedly said that he wants to annex Greenland “very badly,” with a range of options on the table, including a military attack.
Amid opposition from Greenlandic…
Continue Reading
-
Russia hits Ukraine with Oreshnik hypersonic missile: Why it matters | Russia-Ukraine war News
Russia fired its hypersonic Oreshnik missile overnight at Ukraine, Moscow confirmed on Friday, striking a city barely miles away from the Ukrainian border with Poland, at a time when efforts to forge a peace deal are sputtering.
Some experts say…
Continue Reading
-
ISS astronaut medical evacuation latest news: SpaceX readies Dragon spacecraft for Crew-11 return to Earth
Refresh
SpaceX prepares for Crew-11 medical evacuation
(Image credit: NASA) SpaceX says it’s Dragon spacecraft at the International Space Station is ready to return its four Crew-11 astronauts home in an…
Continue Reading
-
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension
Competing interests
P.N.: Medical writing support for the manuscript as declared in the Acknowledgments; consulting fees from Amicus, Chiesi, Greenovation, Idorsia, Sanofi-Genzyme, Takeda; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amicus, Chiesi, Greenovation, Idorsia, Sanofi-Genzyme, Takeda; participation on a data safety monitoring board or advisory board for Amicus, Chiesi, Greenovation, Idorsia, Sanofi-Genzyme, Takeda. O.G.-A.: Medical writing support for the manuscript as declared in the Acknowledgments; grant support from Idorsia, Sanofi, Protalix, Chiesi, Sangamo, 4DMT for clinical research trials; grant support from Sanofi and Takeda for other investigator-initiated studies; has/will receive(d) consulting fees from Sanofi, Chiesi, Takeda, Uniqure; payment or honoraria for speaker bureaus for Sanofi and Takeda; participation on an advisory board on Fabry disease for Chiesi and Sanofi. J.B.: Medical writing support for the manuscript as declared in the Acknowledgments; research support for clinical trial from Idorsia Pharmaceuticals; research support from AVROBIO, BioMarin Pharmaceutical, Chiesi Farmaceutici, Pfizer, Protalix BioTherapeutics, Sangamo Therapeutics, Sanofi, Takeda, Travere Therapeutics; consulting fees from Chiesi USA and Takeda for advisory boards; speaker honorarium from Fabry Support and Information Group. D.P.G.: Medical writing support for the manuscript as declared in the Acknowledgments; consulting fees from Chiesi, Idorsia, Sanofi, and Takeda; support for attending meetings and/or travel from Chiesi, Sanofi, and Takeda. P.G.: Medical writing support for the manuscript as declared in the Acknowledgments. A.J.: Medical writing support for the manuscript as declared in the Acknowledgments; research grants from Takeda and Amicus; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Amicus, Chiesi, Takeda, and Sanofi; support for attending meetings and/or travel from Amicus and Chiesi. V.K.: Medical writing support for the manuscript as declared in the Acknowledgments; payment for expert testimony from Sanofi; participation on a Pompe disease advisory board for Sanofi; PI of trials for Protalix and Idorsia. K.N.: Medical writing support for the manuscript as declared in the Acknowledgments; research/clinical trial funding to institution from Sanofi, Takeda, Amicus and Idorsia; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Takeda, Sanofi and Amicus; participation on a data safety monitoring board or advisory board for Takeda, Sanofi and Amicus. C.R.G.: Medical writing support for the manuscript as declared in the Acknowledgments. R.S.: Medical writing support for the manuscript as declared in the Acknowledgments. M.T.: Medical writing support for the manuscript as declared in the Acknowledgments. A.T.-S.: Medical writing support for the manuscript as declared in the Acknowledgments. E.W.: Medical writing support for the manuscript as declared in the Acknowledgments; grants or contracts from Sanofi, Idorsia, Chiesi, Protalix, Walking Fish Therapeutics, Spark Therapeutics; consulting fees from Sanofi, Amicus, Chiesi, Protalix, Walking Fish Therapeutics, Spark Therapeutics; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Sanofi, Chiesi, and Natera; support for attending meetings and/or travel from Sanofi, Chiesi, and Protalix. R.W.: Medical writing support for the manuscript as declared in the Acknowledgments; employed by Idorsia (the study funder) during the planning and execution of the study; owns stock in Idorsia. M.W.: Medical writing support for the manuscript as declared in the Acknowledgments; contract for research from Chiesi; grants from Takeda, Sanofi and Amicus; IP for Fabry gene therapy and Fabry cardiac biomarkers; consulting fees from Takeda; honoraria for CME presentations from Takeda, Sanofi and Sumitomo; payment for expert testimony from Takeda and Amicus; support for travel expenses from Amicus; participation on advisory boards for Sanofi and Amicus; Chair of the Scientific Committee for the CFDI Registry; Member of the Fabry Outcome Survey Steering Committee for Takeda; Member of the Scientific Committee for the Canadian Symposium on Lysosomal Diseases; Member of the North American Advisory Board for Sanofi; Member of the Scientific Committee for the Fabry Update Meeting. M.C.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; shareholder of Idorsia Pharmaceuticals Ltd. A.F.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; shareholder of Idorsia Pharmaceuticals Ltd. L.T.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals (Sponsor) at the time of data generation, statistical evaluation, and data interpretation; shareholder of Idorsia Pharmaceuticals Ltd. M.M.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; owns stock. M.V.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; shareholder of Idorsia Pharmaceuticals Ltd. C.W.: Medical writing support for the manuscript as declared in the Acknowledgments; grant(s) from Boehringer Ingelheim and Sanofi; consultancy fees from Amgen, Amicus, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Vifor Pharma, Chiesi, Chugai, Fresenius Medical Care, GSK, Idorsia, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi. D.H.: Medical writing support for the manuscript as declared in the Acknowledgments; consultancy fees for advisory boards from Idorsia, Amicus, Sanofi, Takeda, Chiesi, Freeline, Sangamo; honoraria for speaking from Idorsia, Amicus, Sanofi, Takeda, Chiesi, Freeline, Sangamo; support for attending meetings and/or travel from Amicus, Sanofi, Freeline, Chiesi.
Continue Reading
-
Scientists Capture Plants Breathing Live for First Time
Scientists have captured the process of plants “breathing” in real time using a camera, marking a significant scientific breakthrough.
For many years, researchers have known that plants take in air through tiny pores on their leaves…
Continue Reading